Navigation Links
Neuralstem Completes $5.25 Million Financing
Date:2/18/2010

ROCKVILLE, Md., Feb. 18 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE AMEX: CUR) announced today that it has raised a total of $5,228,000 since the beginning of the year, comprised of a previously disclosed $1.5 million private placement of 646,551 common shares at $2.32, priced at a 30 percent premium over the market on the closing, and approximately $3.7 million from warrant exercises.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

Neuralstem also is pleased to announce that it received notice from the NYSE Amex that the Company is now in compliance with its listing requirements.

"These funds will help to support the development of our stem cell technology, including our ongoing clinical trial at Emory University," stated Richard Garr, President and CEO of Neuralstem. "We are also pleased that the NYSE Amex has recognized the improvement in Neuralstem's financial position."

About Neuralstem, Inc.

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous system diseases including: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. ALS is a progressive fatal neurodegenerative disease that affects nerve cells in the brain, leading to the degeneration and death of the motor neurons in the spinal cord that control muscle movement. Pre-clinical work has shown that Neuralstem's cells extended the life of rats with ALS (as reported in the journal TRANSPLANTATION, October 16, 2006, in collaboration with Johns Hopkins University researchers), and also reversed paralysis in rats with Ischemic Spastic Paraplegia (as reported in NEUROSCIENCE, June 29, 2007, in collaboration with researchers at University of California San Diego).

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2008 and the quarterly report on form 10-Q for the period ended September 30, 2009.

SOURCE Neuralstem, Inc.

RELATED LINKS
http://www.neuralstem.com

'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
2. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
4. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
5. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
6. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
7. Neuralstem Reports Second Quarter Financial Results and Highlights
8. Neuralstem Fills Key Product Development Position
9. Neuralstem Responds to New StemCells, Inc. Lawsuit
10. Neuralstem Sues StemCells, Inc. Over New Patent
11. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... 2017 , ... G-CON today announced that it has received ... Patent Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile Clean Room. The ... protection of G-CON’s R&D investments and validate the G-CON platform as a novel ...
(Date:7/17/2017)... ... July 17, 2017 , ... Whitehouse Laboratories ... capabilities to encompass the full series of ISO 80369 standard test procedures. The ... medical device and drug delivery systems. With this recent expansion, Whitehouse Labs becomes ...
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental disorders (NDDs) ... of overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) has been ... and testing. , However, designing a custom panel for disease research requires ...
(Date:7/16/2017)... ... July 16, 2017 , ... OHAUS Corporation, a leading worldwide ... its new line of Rocking and Waving Shakers today. , Five New Models ... and digital) for laboratory applications in a variety of environmental conditions. Rocking shakers ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext Inc., a global ... of a media edge server, the M820, which features the company,s ... recognition software provided by Tera Probe, Inc., will be showcased during ... at the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):